Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics)

全人源抗CD19和CD22自体T细胞（驯鹿医疗）

Report date: 2024/01/31 16:52:23

Base Information

Drug NameAnti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics)
Drug Alias Name全人源抗CD19和CD22自体T细胞注射液CT-120
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A